While short-term efficacy in core symptoms should be demonstrated first, EMA draft drug development guidance also calls for a showing of positive effect on global function and maintenance of long-term efficacy.

Novo Nordisk aligns with Xoma to develop monoclonal antibodies that could up-regulate the insulin receptor, and also signs an R&D pact with Ablynx. Takeda and Teva agree to joint venture in Japan built around the Japanese pharma's mature products.